Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company. These documents include current reports on Form 8-K and other periodic reports in which OPKO discloses financial results, significant transactions and operational updates.
Form 8-K current reports capture material events such as the announcement of quarterly operating and financial highlights and the completion of notable transactions. For example, OPKO has filed an 8-K describing a press release with results of operations and financial condition for a quarter, and another 8-K detailing the completion of the sale of certain BioReference Health oncology and related clinical assets to Labcorp under an asset purchase agreement.
Through its SEC filings, OPKO outlines segment performance in its pharmaceutical and diagnostics activities, provides information on capital structure changes such as convertible note exchanges, and describes collaboration agreements and asset sales. Exhibits to these filings often include press releases that summarize business highlights and explain how to access related conference calls and webcasts.
On Stock Titan, OPKO’s SEC filings are updated as they become available from the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as quarterly results, transaction terms, and other events described in Forms 8-K and other filings. Users can quickly identify filings that discuss diagnostics operations at BioReference, collaborations involving ModeX Therapeutics, and other developments that OPKO reports to regulators and investors.
OPKO Health is calling a virtual 2026 annual stockholder meeting on June 18, 2026, asking investors to elect 11 directors, approve a new 2026 Equity Incentive Plan, give an advisory Say on Pay vote, and ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record on April 20, 2026, holding 755,092,256 outstanding common shares, are entitled to one vote per share and may vote online, by phone, or by mail. The proxy details a board where independent directors form a majority and chair all key committees, and shows significant insider and large‑holder ownership, including 33.31% beneficial ownership by CEO Phillip Frost, M.D.
OPKO Health is calling a virtual 2026 annual stockholder meeting on June 18, 2026, asking investors to elect 11 directors, approve a new 2026 Equity Incentive Plan, give an advisory Say on Pay vote, and ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record on April 20, 2026, holding 755,092,256 outstanding common shares, are entitled to one vote per share and may vote online, by phone, or by mail. The proxy details a board where independent directors form a majority and chair all key committees, and shows significant insider and large‑holder ownership, including 33.31% beneficial ownership by CEO Phillip Frost, M.D.
OPKO Health reported first‑quarter 2026 revenue of $124.2M, down from $150.0M a year earlier, as service revenue declined while product and intellectual property revenue grew modestly. Total costs and expenses fell to $175.2M, improving the operating loss to $51.0M from $67.2M.
Net loss narrowed to $54.8M, or $0.07 per share, compared with a $67.6M loss, or $0.10 per share, in the prior‑year quarter. Cash, cash equivalents and restricted cash were $355.6M at March 31, 2026, with net cash used in operating activities improving to $19.3M from $34.6M.
Total assets were $1.86B and total liabilities $652.2M, leaving shareholders’ equity of $1.20B. The company continued its repurchase program, buying 3.95M shares for about $4.8M in the quarter, and remains exposed to foreign exchange movements, with 32.7% of revenue in non‑U.S. currencies.
OPKO Health reported first quarter 2026 results showing lower revenue but narrower losses as it reshapes its business. Total revenue was $124.2 million versus $149.9 million a year earlier, largely reflecting the prior sale of certain BioReference oncology assets.
Operating loss improved to $51.0 million from $67.2 million, and net loss narrowed to $54.8 million, or $0.07 per share, compared with a net loss of $67.6 million, or $0.10 per share. Pharmaceuticals revenue grew to $52.0 million, helped by higher international sales and increased NGENLA profit share, while diagnostics revenue declined to $72.2 million after the oncology divestiture.
Cash, cash equivalents, marketable securities and restricted cash totaled $341.9 million as of March 31, 2026. The company repurchased approximately $92.0 million of stock since its July 2025 authorization, including $4.8 million in the quarter, with about $108.0 million remaining available.
Opko Health director John A. Paganelli bought 10,000 shares of common stock in an open-market purchase at $1.135 per share. After this transaction, he directly holds 394,340 shares. An additional 9,175 shares are owned by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest.
OPKO HEALTH, INC. director Uppaluri Subbarao V received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.17 per share and were awarded at no cost to the director. According to the filing, these options become exercisable on March 18, 2027 and expire on March 17, 2036. Following this grant, the director holds stock options for 50,000 underlying shares.
OPKO HEALTH, INC. director Dr. Uppaluri Subbarao V filed an initial Form 3 reporting his ownership of the company’s common stock. He reports direct ownership of 622,817 shares and several indirect interests through family-related entities and trusts.
One indirect position is held by Uppaluri Investments, LLC, which is owned equally by the Uppaluri 2012 Family Trust and the Ajay Uppaluri 2020 Gift Trust. Additional indirect holdings are reported through the 2020 Trust and shares owned by his spouse. For each of these indirect positions, Dr. Uppaluri disclaims beneficial ownership except to the extent of his pecuniary interest.
OPKO Health, Inc. has appointed Subbarao V. Uppaluri, Ph.D. as a new independent director, effective March 18, 2026. He will serve until the 2026 Annual Meeting of Stockholders and is expected to join the Compensation Committee.
Dr. Uppaluri previously served as OPKO’s Senior Vice President and Chief Financial Officer from 2007 to 2012 and later as a consultant. The board cites his independence under SEC and Nasdaq rules and notes there are no related-party transactions requiring disclosure. He fills a vacancy created by the passing of longtime director Dr. Richard Krasno and will receive the company’s standard non-employee director compensation and indemnification protections.
OPKO Health files its annual report detailing a diversified healthcare business spanning pharmaceuticals and diagnostics. The company highlights NGENLA®, a once-weekly growth hormone partnered with Pfizer, which generated $31.9 million in 2025 royalty and profit-share payments and is approved in more than 50 countries.
OPKO emphasizes Rayaldee, an FDA‑approved treatment for secondary hyperparathyroidism, now launched or authorized across multiple international markets through partners VFMCRP and Nicoya. Its ModeX subsidiary is advancing multispecific antibody and vaccine platforms, supported by BARDA funding and collaborations with Merck and Regeneron.
In diagnostics, OPKO reshaped BioReference by divesting non-core assets to Labcorp for up to $462.5 million, cutting annual revenue by about $200 million but reducing headcount from roughly 3,300 to 1,373 and refocusing on New York/New Jersey clinical testing and the 4Kscore® prostate cancer test, whose revenue grew more than 13% in 2025.
OPKO Health reported weaker results for the quarter and year ended December 31, 2025, while highlighting major new partnerships and a deepening pipeline. Fourth quarter revenue was $148.5 million versus $183.6 million a year earlier, with a net loss of $31.3 million, or $0.04 per share, compared with net income of $14.0 million in 2024.
For full year 2025, revenue fell to $606.9 million from $713.1 million, and net loss widened to $225.7 million from $53.2 million. The company signed a Regeneron collaboration with potential milestones exceeding $200 million per program and overall value above $1 billion, and reported progress across multiple ModeX antibody programs. Cash, cash equivalents and restricted cash were $369.1 million at year-end 2025. OPKO issued 2026 guidance calling for total revenue of $530–$560 million and total costs and expenses of $725–$750 million.